Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Doximity

Doximity, Inc. develops an online healthcare resource and interactive platform. The Company cloud-based platform enables its members to collaborate with their colleagues, securely coordinate patient care, and conducts virtual patient visits. Doximity serves customers in the United States.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Doximity surpasses Q4 revenue expectations and eyes continued growth

Doximity's Q4 2023 performance exceeded expectations, showcasing strong financial metrics and strategic investments. The company's outlook for Q1 2024 indicates continued growth, with a focus on topline expansion and product innovation. While facing challenges in pricing strategies and competitive landscape, Doximity is well-positioned to capitalize on opportunities in the healthcare technology sector.

Doximity reports strong Q1 results but lowers 2024 guidance

Doximity delivered strong financial performance in Q1, but challenges in upsell close rates led to a downward revision in annual guidance. The company's focus on innovation, expansion, and shareholder value, along with a cautious outlook for the remainder of the year, presents a mixed picture of opportunities and challenges for investors.

Doximity reports strong Q3 earnings, eyes growth amid product challenges

Doximity's Q3 performance demonstrated resilience and growth potential despite challenges in meeting annual guidance due to product delays.
The company's focus on innovation, strong client relationships, and strategic investments position it well for future growth and market leadership.
With a commitment to R&D, expanding product offerings, and maintaining pricing discipline, Doximity aims to capitalize on opportunities and navigate challenges for sustained success.

Doximity surpasses Q4 revenue targets, poised for growth and innovation

Doximity's Q4 performance exceeded expectations, with robust revenue growth, strong margins, and strategic investments in new products and talent.
While facing challenges like flat growth in certain segments and pricing adjustments, the company is well-positioned to capitalize on opportunities in network expansion and technology innovation.
With a focus on enhancing user experience, driving engagement, and optimizing revenue streams, Doximity is poised for continued success and value creation for shareholders.
The company's financial health, innovative product offerings, and market positioning indicate a promising outlook for sustained growth and competitive advantage in the healthcare technology sector.

Doximity surpasses Q1 revenue expectations, faces upsell challenges

Doximity's Q1 performance was strong, but challenges in upsells prompted a staff reduction and revised guidance. The company is optimistic about long-term growth, leveraging new products and a self-serve ad platform for future success.

Doximity beats Q2 expectations, eyes growth amidst market uncertainties

Doximity's strong Q2 performance exceeded revenue and EBITDA guidance, driven by record physician engagement and new product success.
While facing market uncertainties and competition challenges, the company sees opportunities in pricing strategies and continued growth.
Investments in high-touch services, Telehealth, and video products are paying off, with a focus on enhancing client offerings.
Integration with IQVIA for real-time ROI analysis positions Doximity for future growth and client value creation.

Doximity beats Q3 revenue, eyes growth through AI products

Doximity's Q3 performance exceeded expectations with strong revenue and margin growth. The company faces challenges with elongated sales cycles but has opportunities for growth through AI products and new modules. Overall, Doximity's competitive position remains strong in the market.

Doximity exceeds Q4 revenue, eyes mid-teens growth post-COVID

Doximity's Q4 earnings call highlighted strong financial performance, customer satisfaction initiatives, and growth opportunities in digital marketing and new business segments. While facing challenges in growth slowdowns and market uncertainties, the company is leveraging strengths in optimized margins, visibility into revenue guidance, and customer commitment to drive future success.

Doximity excels in Q1 2025, driving growth through client value

Doximity's Q1 2025 performance reflects strong revenue growth, operational efficiency, and client value proposition.
The company's focus on innovation, customer engagement, and strategic insights positions it well for sustained growth.
Despite challenges, Doximity's proactive approach to industry dynamics and growth opportunities bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Doximity, Inc. (DOCS) Q3 2024 Earnings Call Transcript

The headline numbers for Doximity (DOCS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Doximity (DOCS) Q3 Earnings: A Look at Key Metrics

Doximity (DOCS) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.22 per share a year ago.

Doximity (DOCS) Q3 Earnings and Revenues Surpass Estimates

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer, its popular telehealth platform, has been named 2024 Best in KLAS in the Telehealth - Video Conferencing Platforms segment. This is the third consecutive year that Doximity has earned the top position. The complete 2024 Best in KLAS: Software & Services report can be found here. In addition to securing the #1 spot, Doximity received.

Doximity Ranked #1 Best in KLAS Telehealth Video Conferencing Platform for Third Consecutive Year

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2024 third quarter ended December 31, 2023. "We're proud to deliver another quarter of double-digit engagement growth across our entire platform, with a beat and raise on both our top and bottom lines,” said Jeff Tangney, co-founder and CEO of Doximity. “Our clinical workflow tools continue to drive daily use among doctors, and we now co.

Doximity Announces Fiscal 2024 Third Quarter Financial Results

Get a deeper insight into the potential performance of Doximity (DOCS) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Countdown to Doximity (DOCS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter ended December 31, 2023 after market close on February 8, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ b.

Doximity to Release Fiscal 2024 Third Quarter Results on February 8, 2024

CVS Health

DexCom

The COVID-19 pandemic highlighted the sometimes fragile nature of the American healthcare system. Many people had to delay elective surgeries and forego other treatments for an extended period.

3 Stocks to Capitalize on the Telehealth Explosion

Doximity Inc is well-positioned to meet and exceed expectations for fiscal 2024 after the online networking service for medical professionals cut its guidance and messaged slower growth, according to analysts at Bank of America.  With "no more shoes to drop," the analysts have upgraded the stock to 'Neutral' from 'Underperform' and lifted their price objective to $29 from $21.

Doximity raised to ‘Neutral' as analysts see limited downside amidst macro challenges

Doximity (DOCS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Doximity (DOCS) Upgraded to Buy: What Does It Mean for the Stock?

Amazon

CrowdStrike

First Solar

GameStop

NVIDIA

AI stock predictions are all the rage, and for good reason. I asked Google's Bard and ChatGPT to give me some predictions regarding which stocks will soar soon.

7 Stocks that Multiple AI Bots Predict Will Soar in the Near Future

Teladoc

Digital health and telemedicine are booming sectors offering attractive opportunities to investors looking to capitalize on the growing demand for remote healthcare. A couple of years ago, the Covid-19 pandemic accelerated the adoption of digital health solutions such as online consultations, remote monitoring, and digital prescriptions.

Future in Fitness: 3 Stocks Innovating in Digital Health

Enfusion

Pubmatic

Fed Chair Jerome Powell's recent comments signal a lenient approach, making it highly unlikely for interest-rate hikes to occur soon, even in the face of a potentially heating economy. This bodes well for American households as the cost of borrowing, from credit cards to mortgages, is expected to decline gradually, along with everyday expenses.

Hidden Gems: 3 Small-Cap Tech Stocks With Huge Potential

Inmode Ltd

Battling significant decelerations in sales growth, both companies are cheaper than ever. One-sixth of Doximity's market capitalization comes from its large cash balance.

2 Magnificent Stocks That Could Go Parabolic

American Well Corporation

Hims & Hers Health

The telehealth sector is undergoing a significant transformation, reshaping the traditional contours of medical service delivery. This innovation-driven domain is drawing attention from investors, as top telehealth stocks show potential in a rapidly expanding market.

5 Telehealth Stocks That Have Nothing But Upside

Doximity (DOCS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Moving Higher for Doximity (DOCS): Time to Buy?

Telehealth stocks were all the rage during the pandemic, with many expecting the valuations of these companies to soar due to people staying home and practicing social distancing. However, as the old normal returned, some investors cast doubt over the long-term viability of telehealth stocks.

Top 3 Telehealth Stocks to Invest in for a Future of Virtual Care

ICON

Investors looking for stocks in the Medical Services sector might want to consider either Icon PLC (ICLR) or Doximity (DOCS). But which of these two stocks offers value investors a better bang for their buck right now?

ICLR or DOCS: Which Is the Better Value Stock Right Now?

The online platform for medical professionals also reported fiscal second-quarter adjusted earnings that beat analysts' estimates.

Doximity Stock Rallies. Guidance Boost 'Just What the Doctor Ordered.

Doximity, Inc. (NYSE:DOCS ) Q2 2024 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Perry Gold - VP of IR Jeffrey Tangney - Co-Founder & CEO Anna Bryson - CFO Nate Gross - Co-Founder & CSO Conference Call Participants Brian Peterson - Raymond James Richard Close - Canaccord Genuity Ryan Daniels - William Blair Scott Berg - Needham & Company Samir Patel - Evercore ISI Jessica Tassan - Piper Sandler Scott Schoenhaus - KeyBanc Craig Hettenbach - Morgan Stanley Jailendra Singh - Truist Securities Allen Lutz - Bank of America Glen Santangelo - Jefferies David Larsen - BTIG Operator Good afternoon. My name is Krista and I'll be your conference operator today.

Doximity, Inc. (DOCS) Q2 2024 Earnings Call Transcript

Although the revenue and EPS for Doximity (DOCS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Doximity (DOCS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2024 second quarter ended September 30, 2023. “We're proud to make medicine mobile, with another quarter of record engagement across our entire platform,” said Jeff Tangney, co-founder and CEO of Doximity. “Over 550,000 unique providers used our generative AI, telehealth, messaging, and scheduling workflow tools in Q2 to provide better c.

Doximity Announces Fiscal 2024 Second Quarter Financial Results

Doximity (DOCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced DocDefender, a free service for physicians that tracks down and eliminates their personal contact information from public websites. In an environment of escalating violence and harassment against health care professionals, Doximity developed DocDefender to help doctors protect themselves and their families by taking control of their private information online.

Doximity Launches DocDefender, Expanding Services to Safeguard Physician Privacy

Progyny

Progyny's fertility solutions continue to be far more efficient than national averages. Doximity is weathering a downturn in the ad industry but should only grow in importance.

News for Doximity Stock (DOCS)